This item first appeared in 2007
Churchill College, Cambridge, 5-7 December 2007
The area of Process Development continues to be a challenging and important area for the research into and application of modern synthetic organic chemistry as well as enabling technologies.
The symposium aimed to bring together a wide range of speakers from across the pharmaceutical, agrochemical and fine chemical industries as well as from an academic background.
| Programme | ||
| Wednesday 5 December | ||
| Chairman - Dr David Lathbury, AstraZeneca, UK | ||
| 13:40 | Diastereoselective Reductive Amination of 2,2,2- Trifl uoroacetophenones and a-Aminoesters (pdf 280Kb) Dr Greg Hughes, Merck-Frosst, Canada | |
| 14:20 | Process Aspects of Asymmetric Hydrogenation (pdf 680Kb) Dr Ian Lennon, DowPharma, UK | |
| 15:00 | Lab Automation within Roche Synthesis & Process Research and Kilolaboratory Dr Jean-Michel Adam, F. Hoffman-La Roche Ltd., Switzerland | |
| 15:40 | Tea Process Chemistry Retrospectives | |
| 16:10 | SK&F92334 - Chemical Development of the Original Blockbuster Dr Mike Forth, GlaxoSmithKline, UK | |
| 16:40 | Atenolol - 30 years of Life Cycle Management (pdf 2.2Mb) Dr Stewart Jolly, AstraZeneca, UK | |
| 17:10 | 'A Blast from the Past' - Removal of Azide Protection in the Identification and Development of a Manufacturing Process to Amlodipine (pdf 80Kb) Mr Alan Pettman, Pfizer Global Research & Development, UK | |
| Thursday 6 December | ||
| Chairman- Dr Martin Jones, AstraZeneca, UK | ||
| 09:00 | MK-524 - A Study in Modern Chemical Development (pdf 1.3Mb) Dr Edward Grabowski, Merck Research Laboratories (retired), USA | |
| 10:00 | The Chemical Development of Tofi milast a PDE4 Inhibitor for Asthma and COPD (pdf 350 Kb) Dr Lorraine Murtagh, Pfizer Global Research & Development, UK | |
| 10:40 | Coffee | |
| 11:10 | ZK-EPO, Chemical Development of a Totally Synthetic Epothilone Anti Cancer Drug Dr Harribert Neh, Bayer Schering Pharma AG, Germany | |
| 11:50 | Green Manufacture of Chiral Alcohols using Custom Evolved Biocatalysts - Replacing Boron Based Reducing Agents Dr Jim Lalonde, Codexis Inc, USA | |
| 12:30 | The Optimization and Scale-up Synthesis of BCL-2 Inhibitors Dr David Hill, Abbott Laboratories, USA | |
| Chairman - Dr John Carey, GlaxoSmithKline, UK | ||
| 14:10 | Large-Scale Application of Microreaction Technology within Commercial Chemical Production of DSM | |
| 14:50 | The Synthesis of 9-Oxa-3,7-diazabicyclo[3.3.1]nonanes (Oxabispidines) and their use as Pharmaceutical Intermediates Dr David Cladingboel, AstraZeneca, UK | |
| 16:00 | Increasing Process Understanding through Data Analysis (pdf 500Kb) Dr Alan Brown, Syngenta, UK | |
| 16:40 | Process Research over 25 Years: A Personal Perspective (pdf 4.5Mb) Professor Steven Ley, University of Cambridge, UK | |
| Friday 7 December | ||
| Chairman - Dr Graham McDougald, Syngenta, UK | ||
| 09:00 | Process Development of Brivanib Alaninate, a VEGRF/FGFR Inhibitor Dr Paul Lobben, Bristol-Myers Squibb, USA | |
| 09:40 | Directed Evolution of Enzymes: New Biocatalysts for Organic Synthesis Professor Nick Turner, University of Manchester Winner of GlaxoSmithKline, AstraZeneca and Pfizer Prize for Process Chemistry Research 2007 | |
| 11:10 | Redesigning and Developing the Synthetic Route to 435466 Dr David Catterick, GlaxoSmithKline, UK | |
| 11:50 | Green Chemistry in the Pharmaceutical Industry Dr Andy Wells, AstraZeneca, UK | |
Visit Blog